A Study of the HSP90 Inhibitor AUY922

NCT01485536 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

OTHER

Sponsor class

Stopped Study halted early due to limited response.

Conditions

Lymphoma

Interventions

DRUG: AUY922

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]